BRIDGEWATER, NJ - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) and Strides Pharma Science Limited (“Strides”) today announced the addition ofIcosapent ethyl acid soft gel capsules, a product referencing VASCEPA^®. The product has been in-licensed from Strides, a global pharmaceutical manufacturer, and will be commercialized by Amneal starting in the fourth quarter of 2023.

Icosapent ethyl acid soft gel capsules 0.5g and 1g is an ethyl ester of eicosapentaenoic acid (EPA) that is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

“We are on-track to launch over 40 new products in 2023,” said Andy Boyer, Executive Vice President, Amneal Generics. “The launch of Icosapent ethyl is another essential medicine that we’ve added to our portfolio.”

“We are thrilled to announce our partnership with Amneal Pharmaceuticals for Icosapent ethyl acid soft gelatin capsules. This partnership is a testament to our commitment to excellence and the pursuit of cutting-edge solutions. By combining our resources, expertise, and shared passion, we are confident that we will achieve remarkable outcomes that benefit not only our organizations but also our valued customer and stakeholders,” said Aditya Kumar, Vice President Business Development, Strides Pharma Science Limited.

Important Safety Information: Adverse effects reported with VASCEPA^® include musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation. For full prescribing information, see package insert located here.